Kiran Mazumdar-shaw

Biocon Q2FY26 results: Consolidated net profit at ₹84.5 cr, revenue up 21%

The biosimilars segment, operated by Biocon Biologics, reported revenues of Rs 2,721 crore, reflecting strong 25 per cent year-on-year growth

DK Shivakumar meets Biocon's Kiran Mazumdar-Shaw amid Bengaluru infra row

Karnataka Deputy CM DK Shivakumar met Biocon chief Kiran Mazumdar-Shaw a week after she raised concerns over Bengaluru's poor infrastructure, sparking an online discussion on the issue

Biocon chief Kiran Mazumdar-Shaw meets CM Siddaramaiah, deputy CM on Diwali

Biocon chief Kiran Mazumdar-Shaw on Tuesday met Chief Minister Siddaramaiah and his deputy D K Shivakumar and greeted them on the occasion of Diwali, official sources said. Shaw has been critical of Bengaluru's infrastructure woes by highlighting them through her social media posts, and has been repeatedly urging the state government to intervene. "Biocon chief Kiran Muzumdar-Shaw visited Cauvery (CM's official residence) and wished Chief Minister Siddaramaiah on Diwali. Legislative Council Chairman Basavaraj Horatti was present on the occasion," the CM's office said in a statement. Shah met Shivakumar at his Sadashivanagar residence in Bengaluru, the Deputy CM's office said. The state government has come under criticism over the poor state of roads and traffic issues in the city for some time now, with industry veterans like former Infosys CFO Mohandas Pai and Shaw repeatedly openly urging the state government to immediately intervene. Faced with mounting criticism from industry

Biocon chief Kiran Mazumdar-Shaw slams IndiGo's food menu, sparks debate

The airline ensured that it would enhance the offerings and thanked her for sharing feedback, noting that customer opinions help them improve

Biocon's Kiran Mazumdar-Shaw flags Bengaluru road woes; minister responds

Responding to Shaw's criticism, Karnataka minister Priyank Kharge said he was unsure which part of Bengaluru her overseas visitor has seen

Biocon chief Kiran Mazumdar-Shaw lauds Bengaluru talent, slams poor infra

Biocon Biologics chief urged swift fixes to garbage, debris and roads, saying Bengaluru can be among the world's best; Deputy CM Shivakumar assured action

Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base

Biocon opens Rs 4,500-crore qualified institutional placement to repay debt, invest in Biocon Biologics and meet general corporate obligations

India Inc condemns tragic Pahalgam attack, backs fight against terror

Terrorism is a threat to all of humanity and must be condemned in every form, says Ambani

Cell & gene therapy statrtup Immuneel unveils CAR-T cancer therapy in India

Immuneel Therapeutics, backed by entrepreneur Kiran Mazumdar-Shaw, offers therapy for CAR T-cell therapy for adult B-cell non-hodgkin lymphoma (B-NHL)

Kiran Mazumdar gets 'Jamsetji Tata Award' for biosciences movement in India

Biocon Group Chairperson Kiran Mazumdar-Shaw was conferred the prestigious Jamsetji Tata Award by the Indian Society for Quality (ISQ) on Saturday for pioneering the biosciences movement in India. "This award holds a very special meaning to me as it is named after one of India's greatest visionaries - a man whose legacy of excellence, innovation, and nation-building continues to inspire us all. Jamsetji Tata's commitment to quality and his belief in the transformative power of industry to serve society resonate deeply with my own journey," said Mazumdar-Shaw. The Jamsetji Tata Award, instituted in 2004 by ISQ recognises business leaders who have made significant contributions to Indian society. The Award was announced at the ISQ Annual Conference 2024, held in Bengaluru. Mazumdar-Shaw received the award from Janak Kumar Mehta, President of ISQ and Chairman and Managing Director, TQM International. "This Lifetime achievement award is being presented to Kiran Mazumdar-Shaw for being

Kiran Mazumdar gets 'Jamsetji Tata Award' for biosciences movement in India

Biocon Group Chairperson Kiran Mazumdar-Shaw was conferred the prestigious Jamsetji Tata Award by the Indian Society for Quality (ISQ) on Saturday for pioneering the biosciences movement in India. "This award holds a very special meaning to me as it is named after one of India's greatest visionaries - a man whose legacy of excellence, innovation, and nation-building continues to inspire us all. Jamsetji Tata's commitment to quality and his belief in the transformative power of industry to serve society resonate deeply with my own journey," said Mazumdar-Shaw. The Jamsetji Tata Award, instituted in 2004 by ISQ recognises business leaders who have made significant contributions to Indian society. The Award was announced at the ISQ Annual Conference 2024, held in Bengaluru. Mazumdar-Shaw received the award from Janak Kumar Mehta, President of ISQ and Chairman and Managing Director, TQM International. "This Lifetime achievement award is being presented to Kiran Mazumdar-Shaw for being

Bioengineering is really the way we have to move forward: Mazumdar-Shaw

Says today, we are at an inflection point when it comes to technology. Up until now, we used to scratch at the surface because we couldn't really understand the mysteries of biology

Need innovation-driven value creation in biotech: Kiran Mazumdar-Shaw

Biocon Chairperson Kiran Mazumdar-Shaw on Thursday called for more investment in research and development to drive innovation and foster culture of intellectual property. She highlighted how the country, already the world's largest exporter of generics and a major player in vaccine production, can achieve greater value by nurturing innovation. Mazumdar-Shaw called for a shift in focus toward value creation through innovation. "India ranks 14th in terms of value in the global pharma landscape. We need to invest in R&D and foster a culture of intellectual property to capture greater value," she said. Addressing a session during the Global Bio-India 2024 event, she positioned the country as a future global leader in biosciences and innovation. Mazumdar-Shaw emphasized India's unique advantages in becoming a global bio-innovation hub, citing the nation's rich scientific talent, robust technological capabilities, and entrepreneurial drive. "Biology is not only the most exciting and ...

May look to bring Liraglutide via clinical trial waiver: Mazumdar-Shaw

Kiran outlines how being vertically integrated puts Biocon in a strong position

Biocon signs licensing, supply deal for obesity drug in South Korea

Bengaluru-based company announces 'strategic partnership' with Handok

Biocon Biologics partners with Sandoz Australia to sell cancer drugs

The partnership will provide Sandoz the exclusive rights to promote, sell, and distribute biosimilar Trastuzumab and biosimilar Bevacizumab in Australia

Biocon inks pact with Sandoz for sale of 2 biosimilar products in Australia

Biocon Biologics on Friday said it has inked a five-year pact with pharmaceutical company Sandoz AG regarding the sale and distribution of two cancer treatment biosimilar products in Australia. The agreement provides Sandoz the exclusive rights to promote, sell and distribute biosimilars Trastuzumab and Bevacizumab in Australia, Biocon Biologics said in a statement. Biocon Biologics is a subsidiary of Biocon Ltd. Under the agreement, Sandoz will distribute the Biocon Biologics' brands, Ogivri (Trastuzumab) and Abevmy (Bevacizumab), and facilitate the sustained access of these medications that were previously distributed by another pharmaceutical company to patients in Australia. Trastuzumab is a biosimilar of Herceptin and Bevacizumab is a biosimilar of Avastin and utilised for the treatment of various cancers. "Following the recent establishment of our strategic partnership with Sandoz in Japan, our agreement with Sandoz in Australia marks another important milestone of our globa

Pharma sector can be of $200 bn by 2030 on innovative drugs: Biocon chief

Research-based incentives to develop innovative drugs can help the domestic pharmaceutical sector to be worth USD 200 billion by 2030, Biocon Executive Chairperson Kiran Mazumdar-Shaw said on Wednesday. Terming the pharmaceutical sector as a great contributor in the country's economic growth, she noted that the industry has even greater potential to grow in the years to come. "India's pharma industry size is estimated at about USD 65 billion today. And by 2030, it is expected to increase to USD 165 billion. Now, I believe it has a potential to even be greater and touch USD 200 billion by 2030," Mazumdar-Shaw told PTI. But such a level of growth cannot just be driven by generics and biosimilars, it has to involve drug innovation, she noted. "We have time to develop new drugs which could be blockbusters and I think what is required are research incentives to drive this kind of growth," Mazumdar-Shaw stated. The government has already come out with various research-linked incentive .

Biocon considers selling generic API biz; turn into biosimilar major

The generic API business has been one of the primary businesses for Biocon, however, in recent years, the segment's contribution towards the company's consolidated financials has declined

Biocon considers selling generic API biz; turn into biosimilar major

The generic API business has been one of the primary businesses for Biocon, however, in recent years, the segment's contribution towards the company's consolidated financials has declined